TBC1D13

Across TCGA pan-cancer cohorts, TBC1D13 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TBC1D13 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TBC1D13 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TBC1D13 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, UCEC, and PDAC are the cancer types where TBC1D13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	II,III,IV	1.000	0.767	.005	36	view →
UCEC	DFS	Quartile	III,IV	0.412	1.000	.040	4	view →
PDAC	DFS	Median	II,III,IV	0.458	0.322	.029	4	view →
HNSC	DFS	Median	II,III,IV	0.563	0.762	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TBC1D13–CCRCC (OS)

Open the CCRCC breakdown →